Nov 22 (Reuters) - The U.S. Food and Drug Administration

has approved BridgeBio's drug for a rare and deadly

heart condition, the company said on Friday, making it the first

new treatment in a market dominated by Pfizer's ( PFE )

blockbuster Vyndaqel.

The oral drug, branded as Attruby, was approved to treat

adult patients with transthyretin amyloid cardiomyopathy

(ATTR-CM), in which faulty transthyretin proteins accumulate in

the heart and can cause the organ to fail.